{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:01:12Z","timestamp":1790910072315,"version":"4.1.0"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T00:00:00Z","timestamp":1723766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    The optimal treatment for patients with severe aplastic anemia (SAA) who fail an initial course of antithymocyte globulin (ATG) plus cyclosporine has not yet been established. We compared the effectiveness of allogeneic hematopoietic stem cell transplantation (allo-HSCT) (\n                    <jats:italic>n<\/jats:italic>\n                    = 36) with repeated immunosuppressive therapy (IST) (\n                    <jats:italic>n<\/jats:italic>\n                    = 33) for relapsed\/refractory SAA between 2007 and 2022. In the IST group, patients were retreated with ATG (\n                    <jats:italic>n<\/jats:italic>\n                    = 16) or high-dose cyclophosphamide (\n                    <jats:italic>n<\/jats:italic>\n                    = 17). The overall response rate was 57.6% at 6 months and 60.6% at 12 months. In the allo-HSCT group, patients received a transplant from a matched sibling donor (\n                    <jats:italic>n<\/jats:italic>\n                    = 6), matched unrelated donor (\n                    <jats:italic>n<\/jats:italic>\n                    = 7), or haploidentical donor (\n                    <jats:italic>n<\/jats:italic>\n                    = 23). All patients achieved neutrophil engraftment, and there were no cases of primary graft failure. The cumulative incidences (CIs) of grades II\u2013IV and III\u2013IV acute graft-versus-host disease (GVHD) were 36.1% \u00b1 0.7% and 13.9% \u00b1 0.3% at day +100, respectively. The 4-year CI of chronic GVHD (cGVHD) was 36.2% \u00b1 0.7%, with moderate to severe cGVHD at 14.9% \u00b1 0.4%. Compared with IST, HSCT recipients showed much higher hematologic recovery rate at 3, 6, and 12 months (63.9%, 83.3%, and 86.1%, respectively,\n                    <jats:italic>p<\/jats:italic>\n                    &amp;lt; 0.001). The estimated 4-year overall survival (OS) (79.8% \u00b1 6.8% vs. 80.0% \u00b1 7.3%,\n                    <jats:italic>p<\/jats:italic>\n                    = 0.957) was similar; however, the failure-free survival (FFS) was significantly better in the HSCT group (79.8% \u00b1 6.8% vs. 56.6% \u00b1 8.8%,\n                    <jats:italic>p<\/jats:italic>\n                    = 0.049). Of note, children in the HSCT cohort were all alive without treatment failures, exhibiting superior OS (100% vs. 50.0% \u00b1 17.7%,\n                    <jats:italic>p<\/jats:italic>\n                    = 0.004) and FFS (100% vs. 50.0% \u00b1 17.7%,\n                    <jats:italic>p<\/jats:italic>\n                    = 0.004) than children in the IST cohort. Subgroup analysis revealed that younger patients (age \u2264 35 years), especially children, and those with refractory SAA benefited more from HSCT. Therefore, for these patients, salvage HSCT may be more preferable than a second course of IST.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2024.1425076","type":"journal-article","created":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T00:23:00Z","timestamp":1723767780000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparison of hematopoietic stem cell transplantation and repeated intensified immunosuppressive therapy as second-line treatment for relapsed\/refractory severe aplastic anemia"],"prefix":"10.3389","volume":"15","author":[{"given":"Lining","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiru","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shulian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengze","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erlie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhe","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengkui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sizhou","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-693481","article-title":"How I treat acquired aplastic anemia","volume":"129","author":"Bacigalupo","year":"2017","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613878","article-title":"Eltrombopag added to standard immunosuppression for aplastic anemia","volume":"376","author":"Townsley","year":"2017","journal-title":"New Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-274019","article-title":"How I treat acquired aplastic anemia","volume":"120","author":"Scheinberg","year":"2012","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103975","article-title":"Horse versus rabbit antithymocyte globulin in acquired aplastic anemia","volume":"365","author":"Scheinberg","year":"2011","journal-title":"New Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1413485","article-title":"Aplastic anemia","volume":"379","author":"Young","year":"2018","journal-title":"New Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13614","article-title":"Similar outcome of upfront-unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia. A study on behalf of the uk paediatric bmt working party, paediatric diseases working party and severe aplastic anaemia working P","volume":"171","author":"Dufour","year":"2015","journal-title":"Br J Haematology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13045-017-0398-y","article-title":"Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant","volume":"10","author":"Xu","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01536-y","article-title":"Novel conditioning regimen for upfront haploidentical hematopoietic cell transplantation in children with severe aplastic anemia and donor-specific anti-hla antibodies","volume":"57","author":"Hashem","year":"2022","journal-title":"Bone marrow Transplant"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.scib.2022.01.024","article-title":"Long-term follow-up of haploidentical transplantation in relapsed\/refractory severe aplastic anemia: A multicenter prospective study","volume":"67","author":"Xu","year":"2022","journal-title":"Sci Bull"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06098.x","article-title":"Retreatment with rabbit anti-thymocyte globulin and ciclosporin for patients with relapsed or refractory severe aplastic anaemia","volume":"133","author":"Scheinberg","year":"2006","journal-title":"Br J Haematology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01693.x","article-title":"Rabbit antithymocyte globulin (R-atg) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy","volume":"107","author":"Di Bona","year":"1999","journal-title":"Br J Haematology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.123760","article-title":"Repeat course of rabbit antithymocyte globulin as salvage following initial therapy with rabbit antithymocyte globulin in acquired aplastic anemia","volume":"100","author":"Cl\u00e9","year":"2015","journal-title":"Haematologica"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-225375","article-title":"High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up","volume":"115","author":"Brodsky","year":"2010","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2004.02.002","article-title":"High-dose cyclophosphamide as salvage therapy for severe aplastic anemia","volume":"32","author":"Brodsky","year":"2004","journal-title":"Exp Hematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/1096-8652(200101)66:1<71::aid-ajh1019>3.0.co;2-d","article-title":"High-dose cyclophosphamide in the treatment of severe aplastic anemia in children","volume":"66","author":"Jaime-P\u00e9rez","year":"2001","journal-title":"Am J Hematol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-135-7-200110020-00006","article-title":"Durable treatment-free remission after high-dose cyclophosphamide therapy for previously untreated severe aplastic anemia","volume":"135","author":"Brodsky","year":"2001","journal-title":"Ann Internal Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(00)03126-3","article-title":"High-dose cyclophosphamide in severe aplastic anaemia: A randomised trial","volume":"356","author":"Tisdale","year":"2000","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2013.01.001","article-title":"High-dose cyclophosphamide compared with antithymocyte globulin for treatment of acquired severe aplastic anemia","volume":"41","author":"Zhang","year":"2013","journal-title":"Exp Hematol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-352328","article-title":"Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia","volume":"119","author":"Scheinberg","year":"2012","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-534743","article-title":"Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug","volume":"123","author":"Desmond","year":"2014","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04266-1","article-title":"Eltrombopag is effective in patients with relapse\/refractory aplastic anemia\u2014Report from a single center in China","volume":"99","author":"Ruan","year":"2020","journal-title":"Ann Hematol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1182\/blood-2016-09-738534","article-title":"Severe aplastic anemia: A prospective study of the effect of early marrow transplantation on acute mortality","volume":"48","author":"Camitta","year":"1976","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(22)00206-x","article-title":"Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (Bmt ctn 1502): A multicentre, single-arm, phase 2 trial","volume":"9","author":"DeZern","year":"2022","journal-title":"Lancet Haematology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.837335","article-title":"Comparison of hematopoietic stem cell transplantation outcomes using matched sibling donors, haploidentical donors, and immunosuppressive therapy for patients with acquired aplastic anemia","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.bbmt.2017.10.007","article-title":"Effect of antithymocyte globulin source on outcomes of hla-matched sibling allogeneic hematopoietic stem cell transplantation for patients with severe aplastic anemia","volume":"24","author":"Chen","year":"2018","journal-title":"Biol Blood marrow transplantation: J Am Soc Blood Marrow Transplant"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1175048","article-title":"Development and validation of early death risk score model for emergency status prediction in very severe aplastic anemia","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/bjh.13853","article-title":"Guidelines for the diagnosis and management of adult aplastic anaemia","volume":"172","author":"Killick","year":"2016","journal-title":"Br J Haematol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.20","article-title":"Haploidentical bmt and post-transplant cy for severe aplastic anemia: A multicenter retrospective study","volume":"50","author":"Esteves","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V73.2.606.606","article-title":"Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results","volume":"73","author":"Champlin","year":"1989","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.04.007","article-title":"Standardizing definitions of hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: A report on behalf of the american society for transplantation and cellular therapy","volume":"27","author":"Kharfan-Dabaja","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B31","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/bmt.2016.223","article-title":"Immunosuppressive therapy versus alternative donor hematopoietic stem cell transplantation for children with severe aplastic anemia who lack an hla-matched familial donor","volume":"52","author":"Choi","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"B32","article-title":"1994 Consensus conference on acute gvhd grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood marrow transplantation: J Am Soc Blood Marrow Transplant"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10075","article-title":"Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: A report from the european group for blood and marrow transplantation (Ebmt)","volume":"92","author":"Locasciulli","year":"2007","journal-title":"Haematologica"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-099168","article-title":"Prospective multicenter trial comparing repeated immunosuppressive therapy with stem-cell transplantation from an alternative donor as second-line treatment for children with severe and very severe aplastic anemia","volume":"111","author":"Kosaka","year":"2008","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1046\/j.1365-2141.1998.00578.x","article-title":"Repeated treatment with horse antilymphocyte globulin for severe aplastic anaemia","volume":"100","author":"Tichelli","year":"1998","journal-title":"Br J haematology"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-498279","article-title":"Management of the refractory aplastic anemia patient: what are the options","volume":"122","author":"Marsh","year":"2013","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23669","article-title":"Horse antithymocyte globulin as salvage therapy after rabbit antithymocyte globulin for severe aplastic anemia","volume":"89","author":"Scheinberg","year":"2014","journal-title":"Am J Hematol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/sj.bmt.1704325","article-title":"Addition of low-dose busulfan to cyclophosphamide in aplastic anemia patients prior to allogeneic bone marrow transplantation to reduce rejection","volume":"33","author":"Dulley","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.09.007","article-title":"Impact of cd34 cell dose and conditioning regimen on outcomes after haploidentical donor hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for relapsed\/refractory severe aplastic anemia","volume":"26","author":"Arcuri","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B41","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/s0037-1963(00)90031-3","article-title":"Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy\u2013the european group for blood and marrow transplantation experience","volume":"37","author":"Bacigalupo","year":"2000","journal-title":"Semin Hematol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13045-019-0775-9","article-title":"Who is the best haploidentical donor for acquired severe aplastic anemia? Experience from a multicenter study","volume":"12","author":"Xu","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"696","DOI":"10.3324\/haematol.2014.115345","article-title":"Current outcome of hla identical sibling versus unrelated donor transplants in severe aplastic anemia: an ebmt analysis","volume":"100","author":"Bacigalupo","year":"2015","journal-title":"Haematologica"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14225","article-title":"Haplo-identical transplantation for acquired severe aplastic anaemia in a multicentre prospective study","volume":"175","author":"Xu","year":"2016","journal-title":"Br J Haematology"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.106096","article-title":"Outcome of aplastic anemia in adolescence: A survey of the severe aplastic anemia working party of the european group for blood and marrow transplantation","volume":"99","author":"Dufour","year":"2014","journal-title":"Haematologica"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2023.03.005","article-title":"[Clinical analysis of 76 patients with severe aplastic anemia treated with haploid hematopoietic stem cell transplantation]","volume":"44","author":"Zhang","year":"2023","journal-title":"Zhonghua xueyexue zazhi"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18779","article-title":"Haematopoietic stem cell transplantation for hepatitis-associated aplastic anaemia and non-hepatitis-associated aplastic anaemia: A propensity score-matched analysis","volume":"201","author":"Li","year":"2023","journal-title":"Br J haematology"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1425076\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T00:23:04Z","timestamp":1723767784000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1425076\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,16]]},"references-count":47,"alternative-id":["10.3389\/fimmu.2024.1425076"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1425076","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,16]]},"article-number":"1425076"}}